This underfollowed biotech company's novel approach may flip the immunotherapy space on its head

Should be high on your radar! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [Unsubscribe]( [This Little-known NASDAQ Company is Working on a Revolutionary “Wonder Drug” to Fight Alzheimer’s, Secondary Progressive Multiple Sclerosis, ALS, and Other Neuroinflammatory Diseases.]( The demand for treating neuroinflammatory diseases such as Alzheimer's and MS continues to grow. One company aims to bring to market a unique drug candidate that could significantly help millions of people suffering from such diseases. The cogs are in motion and the company is working diligently to be successful with its lead candidate Foralumab. Lead candidate, intranasal Foralumab, is the World’s ONLY fully human anti-CD3 mAb! How significant is anti-CD3 mAb? Well, last year , Sanofi acquired Provention Bio for a staggering $2.9 billion for the company's humanized anti-CD3 monoclonal antibody drug, teplizumab. This company’s lead candidate Foralumab has demonstrated a favorable safety profile and clinical response in patients in studies to date. Not long ago the company had exciting news, announcing that it has submitted an FDA request to obtain an Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation! [Discover why Foralumab is quickly gaining recognition across the scientific community and how it could build value for TLSA shareholders!]( --------------------------------------------------------------- This message is a PAID ADVERTISEMENT for Tiziana Life Sciences Ltd (NASDAQ: TLSA) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2450. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Tiziana Life Sciences Ltd (NASDAQ: TLSA) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Tiziana Life Sciences Ltd (NASDAQ: TLSA) on Small Caps Daily website for additional information about the relationship between Interactive Offers and Tiziana Life Sciences Ltd (NASDAQ: TLSA). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click [Unsubscribe](. StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com [Today's Bonus Content: $200 Trillion "AI Phase 2" Moments Away?](